Member Info for chester18

Good morning

In my opinion, I think that maybe my post of yesterday had a slight basis in whimsy and was just an assemblage of my best guessing thoughts.

However ‘in my opinion’ it was a reasonable attempt to explain a possible pathway for the upcoming full and verified data release.

Absolutely C11

The 43rd patient’s scan is about now. Dependant on clinical timings and the health of that person we should have reached the final data position.

Add in at least 3 weeks for all the clinical paperwork and data collation plus verification and we will have a result.

The SCIB1 data and the iSCIB+ data need to be fully confirmed before Scancell can sit down and discuss how this should be presented. They also need to align with any potential suitors before the market is presented with the final outcome of all this collaborative distillation.

July 2nd 2025 is the 183rd day of this year with 182 days remaining.

That is now officially our most optimal date.

But for statistical rigour it would be best to add or take away a few weeks…….

Glad to be of assistance… 🤔

Cheers Rob

It is an interesting mix of intrigue and confusion as to which direction those trades are running.

The answer will probably jump out at us in the next 4 to 8 weeks.

Chester 👍

Hi Rob

Thank you for your reply.

I fully understand that the market makers can take a position either to sell or to buy shares when they are aware that news is on its way. You could say that they gamble on the direction the shares will go, also probably knowing more than us private investors as to how the market will react.

They will definitely not deliberately sell shares knowing they will have to buy back at a higher rate….. therefore in the current Scancell situation why would they ‘Sell’ shares at 9.5p & 9.75p when there is very good evidence that they will have to pay much higher to balance the books.

I’m not convinced that they have inside knowledge that the data is going to be below expectations, thus giving them a profit in a later downward market.

So if they are not selling these shares from fresh air where are they getting them ?

If the market makers are buying those shares in an attempt to stockpile before the news event who would be disposing of Scancell shares so close to a definitive set of results.

Either scenario does not make any sense, so is something else happening ??

Hi Ratcliffewriter

I am definitely not someone who would talk down Scancell but by looking at the last 7 days trades I am confused as to where the Market Makers have found so many millions of shares. Selling said shares at 9.5p and 9.75p when the surrounding the trades for buys and sells were slightly higher in general.

Where it confuses me is, if they are buys why is the SP still under 10p and if they are sells why are those volumes not crashing the SP to under 8p.

If anyone has some plausible explanations please spill the beans ……. 🤔

The SCIB1 data is of no relevance as all positive communications from Scancell are for iSCIB+.

They will deliver both together.

Morning C11

In my humble opinion I would expect the SCOPE results to be both SCIB1 and iSCIB+ Intramuscular jointly.

There would be little point in releasing the SCIB1 data not knowing how it actually compared.

That’s why for me the SCOPE news won’t happen until July. News from ModiFY first.

We sure are but not until mid-year so another month at least for the Scope results.

However there is the possibility that we will have a ModiFY update anytime soon.

Patience is a virtue 👍

Makes no difference what we think or how much we believe in Scancell’s new technology. What matters is that the clinical values are of such quality that it attracts the attention of the biggest companies in the treatment of cancer.

I’m as excited as any shareholder because it’s been a very long road to get this close to definitive clinical data. We’ve endured many a false horizon but these data read-outs do come with huge confidence from all recent Scancell communications.

Moab maybe not the best in the setting of early detection and treatment profile but many patients present late in their cancer development. Parsortix will be extremely useful as a clinical tool in later stage tumours.

What is needed soon is the green light to go on that the Oncology Pharma companies see the Parsortix diagnostic as the best way forward. We need contracts and or a major deal.

This whole process is taking far too much time for an FDA approved diagnostic tool in the hands of a cash poor independent company.

It would fly in the hands of a Large Pharma.

Morning Scinv

It is obvious from your posting history that you abhor any misinformation paraded as fact by Biotech companies trading on the AIM market. Your background suggests a good understanding of the route through ph1 to ph3 and on to commercialisation.

I therefore understand why any Scancell comments that have proven later to be false have riled you.

However, I also glean from some of your posts / answers to questions that you are waiting for the data to make up your mind whether to twist or stick.

I could be wrong but I really do hope we have you posting here for at least the next 18 months because you have bought back in.

Lastly why do you sometimes end posts lmao. I’ve looked it up and it means :

‘Learnedly Academic Moderately Obfuscating’ …. very honest of you 😁

Just found this from a news article…,

Prime Minister Sir Keir Starmer said: “This kind of innovation is nothing short of life-saving and I want to see more of these world-leading treatments being developed in the UK.”

Hi Scinv

I do think that our involvement with the CVLP is important. I cannot imagine that anyone can just rock up to the NHS and be signed to the CVLP. There must be some form of vetting process to ensure ‘value for money’.

So in my ‘non-medical’ rational Scancell have been vetted and passed muster.

And yes the Prime Minster referred directly to the addition of IScib+ Intradermal to the CVLP programme.

‘Speculative Buy’ is probably what I would advise.

The reason being that we have had several indicators that all point towards the data being extremely positive.

A non-executive director buying just under 500,000 shares at a bargain price of 9p.

Two high level and future facing jobs being advertised.

Positivity in all communications from Scancell.

The importance of our involvement with the NHS Cancer Vaccine Launch Pad and the fact that our prime minister commented directly about Scancell’s potential in the fight against melanoma cancer.

All of above indicate that the results should not disappoint, plus we may also have something extra to cheer about when we know how the Modify trial is progressing.

Hi Scinv

The point is the milestone payment for officially starting a phase1 trial.

That would be of material interest to the shareholders and reported.

The deal for the first GlyMab was 2 years ago so if GenMab are going to progress that Mab it’s about time they moved it forward.

Hi C11

As you say last year there were three RNS’s by now about conference attendance.

It will be very interesting if by next Friday there is still no news of any intention to attend. That would raise the question of why ?

It would need more discussion if that is the case but I would expect Scancell to attend some of these upcoming events and therefore Tuesday / Wednesday next week for an RNS to land.

I’m hoping that the Modi1 plus Double CPI cohort in Renal Cell Carcinoma interim results show synergy similar to the improvements shown with SCIB1.

If the numbers look good it boosts the chances of the ModiFY Trial being expanded.

My initial investment in Scancell was solely due to the potential of Moditope.

I would never say that the information you have brought to this board is not well informed or unreliable. The points you have raised come from your understanding of science and the scientific collection of trial data.

What you fail to perceive is that looking from the outside of Scancell’s trials your conclusions could be adding 2 + 2 and getting 6.

But we will soon know for sure and I’ll have to eat humble pie or you will disappear without trace or any sort of acknowledgment that you were wrong.

I get that, its how it goes on a chat board.

And you don’t know that there is anything wrong with iScib+ but you keep on pushing your theory that it’s a dud.

There is a definite chasm between the news emanating from Scancell and your single doubting voice but it doesn’t stop you from casting derision from a lofty seat.

So no ‘fort’ to hold just patience until the data arrives. My only concern is that if the data is outstanding in the setting of Stage 4 patients that the Scancell executive are tough enough to get the best possible deal for all the shareholders.